Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Encephalopathy Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Encephalopathy Overview | 9 | 1 |
| Pipeline Products for Encephalopathy Comparative Analysis | 10 | 1 |
| Encephalopathy Therapeutics under Development by Companies | 11 | 1 |
| Encephalopathy Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Encephalopathy Pipeline Products Glance | 13 | 2 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Encephalopathy Products under Development by Companies | 15 | 1 |
| Encephalopathy Products under Investigation by Universities/Institutes | 16 | 1 |
| Encephalopathy Companies Involved in Therapeutics Development | 17 | 12 |
| Amarantus Bioscience Holdings, Inc. | 17 | 1 |
| Celgene Corporation | 18 | 1 |
| Chiesi Farmaceutici SpA | 19 | 1 |
| Fera Pharmaceuticals, LLC | 20 | 1 |
| GW Pharmaceuticals Plc | 21 | 1 |
| JS Genetics Inc. | 22 | 1 |
| KannaLife Sciences, Inc. | 23 | 1 |
| ProThera Biologics, LLC. | 24 | 1 |
| SciFluor Life Sciences, LLC | 25 | 1 |
| Turing Pharmaceuticals AG | 26 | 1 |
| Versantis | 27 | 1 |
| Zambon Company S.p.A. | 28 | 1 |
| Encephalopathy Therapeutics Assessment | 29 | 9 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 20 |
| Alda-1 - Drug Profile | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| AMRS-001 - Drug Profile | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 3 |
| cannabidiol - Drug Profile | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| diazoxide - Drug Profile | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 2 |
| EUC-001 - Drug Profile | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 1 |
| GWP-42003 - Drug Profile | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 2 |
| melatonin - Drug Profile | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| R&D Progress | 48 | 1 |
| phenobarbitol sodium - Drug Profile | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| R&D Progress | 49 | 1 |
| Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| SF-0034 - Drug Profile | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 1 |
| Stem Cell Therapy for Hematological Malignancies, Non-Malignant Disorders and Hypoxic-ischemic Encephalopathy - Drug Profile | 52 | 1 |
| Product Description | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| R&D Progress | 52 | 1 |
| TRP-005 - Drug Profile | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 1 |
| TRP-601 - Drug Profile | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 1 |
| TUR-004 - Drug Profile | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| VS-01 - Drug Profile | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 1 |
| ZP-053 - Drug Profile | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 1 |
| Encephalopathy Recent Pipeline Updates | 58 | 10 |
| Encephalopathy Product Development Milestones | 68 | 3 |
| Featured News &Press Releases | 68 | 1 |
| Feb 29, 2016: Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE | 68 | 1 |
| Nov 16, 2015: Turing Initiates Dosing in Phase I Clinical Trial of TUR 004 for Epileptic Encephalopathies | 68 | 1 |
| Oct 23, 2015: Turing Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application and Fast Track Designation for TUR-004 | 68 | 1 |
| Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy | 69 | 1 |
| Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy | 70 | 1 |
| Appendix | 71 | 2 |
| Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 72 | 1 |